Research Article
Regional Differences in Amyloid Deposition between 11C-Pib PET Positive Patients with and without Elevated Striatal Amyloid Uptake
Franziska T Scheiwein1,2, Kazunari Ishii1,3,4, Chisa Hosokawa1,4, Hayato Kaida1,Tomoko Hyodo1, Kohei Hanaoka4, Matthias Brendel2, Peter Bartenstein2, Axel Rominger2* and Takamichi Murakami11Department of Radiology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan
2Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
3Neurocognitive Disorders Center, Kindai University Hospital, Osakasayama, Osaka, Japan
4Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Osaka, Japan
- *Corresponding Author:
- Axel Rominger
Department of Nuclear Medicine
Ludwig- Maximilians-University of Munich
Marchioninistr, 15D-81377 Munich, Germany
Tel: +49 89 4400 74650
E-mail: axel.rominger@med.uni-muenchen.de
Received date: March 13, 2017; Accepted date: March 28, 2017; Published date: April 04, 2017
Citation: Scheiwein FT, Ishii K, Hosokawa C, Kaida H, Hyodo T, et al. (2017) Regional Differences in Amyloid Deposition between 11C-Pib PET Positive Patients with and without Elevated Striatal Amyloid Uptake. J Alzheimers Dis Parkinsonism 7:317. doi:10.4172/2161-0460.1000317
Copyright: © 2017 Scheiwein FT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Purpose: In subjects showing an increased level of 11C-Pittsburgh compound B (PiB) in positron emission tomography (PET) imaging of the brain, two groups can be distinguished: those with and without elevated PiB uptake in the striatum. We examined regional PiB uptake differences between these groups, and additionally compared them with PiB-negative subjects. Methods: This study included 141 subjects complaining of cognitive impairment. Their clinical diagnoses were Alzheimer’s disease (AD), mild cognitive impairment, dementia with Lewy bodies, frontotemporal lobar degeneration, or subjective cognitive impairment. PiB and 18F-fluorodeoxy-D-glucose (FDG) PET were performed in all subjects. PiB PET images were visually classified into three groups: 1) PiB-positive with uptake in any region of the cortex accompanied by striatal PiB uptake (STRPOS), 2) PiB-positive with cortical uptake but without striatal PiB uptake (STRNEG), and 3) both cortex and striatum PiB-negative (PiBNEG). Standardised uptake value ratios (SUVR) and regional differences in PiB uptake were evaluated using voxelbased analysis of PiB and FDG uptake images. Results: Eighty subjects were visually rated as PiB-positive: 11 had no increased PiB uptake in the striatal area, while 69 showed an elevated striatal PiB level. Sixty-one subjects were PiB-negative. Mean cortical SUVR was 1.46 ± 0.23 for STRNEG, 2.00 ± 0.44 for STRPOS and 0.99 ± 0.19 for PiBNEG. Apart from the striatum, PiB accumulation in the medial orbitofrontal cortex of STRPOS subjects was higher than in STRNEG subjects. No significant differences in regional FDG distribution were observed. Conclusion: PiB-positive cases with high striatal PiB uptake have an increased mean cortical SUVR in comparison to PiB-positive subjects without striatal uptake. This difference is most distinctive in the orbitofrontal cortex. We conclude that a high amyloid load in the striatum is linked to amyloid deposition occurring mostly in the frontal region, and may occur later in the course of AD progression.
